KEYLIKA

Our first product is a novel drug (new molecular entity) in a skin patch to treat Iron Deficiency Anemia, with significantly improved safety, efficacy and tolerability. When approved, Keylika's proprietary transdermal iron will be the world's first prescription iron patch... We have developed a platform synthesis technology for mixed ligand metal complexes that is used to generate a multitude of organometallic drugs for treating a wide range of therapeutic conditions: hematology, pain and inflammation, metabolic disorders to infectious diseases and oncology. We then administer these drugs using proven delivery technologies, to effect the best clinical outcomes. Positioned at the intersection of drug development and drug delivery, enables us to customize the molecular structure and/or formulation as well as add microsystems engineering elements, to optimize the drug delivery per clinical requirements.